Inotiv's gross profit for the
three
months ended in Dec. 2023 was $33.5 Mil. Inotiv's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $177.2 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Inotiv's gross profit for the
three
months ended in Dec. 2023 was $33.5 Mil. Inotiv's Revenue for the
three
months ended in Dec. 2023 was $135.5 Mil. Therefore, Inotiv's Gross Margin % for the quarter that ended in Dec. 2023 was 24.70%.
Inotiv had a gross margin of 24.70% for the quarter that ended in Dec. 2023 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Inotiv was 33.65%. The lowest was 21.65%. And the median was 31.28%.
Warning Sign:
Inotiv Inc gross margin has been in long-term decline. The average rate of decline per year is -1.6%.
Inotiv Gross Profit Historical Data
The historical data trend for Inotiv's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Inotiv's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Gross Profit distribution charts can be found below:
* The bar in red indicates where Inotiv's Gross Profit falls into.
Inotiv Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Inotiv's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $177.2 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Inotiv's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Inotiv (NAS:NOTV) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Inotiv had a gross margin of 24.70% for the quarter that ended in Dec. 2023 => Competition eroding margins
Inotiv Gross Profit Related Terms
Thank you for viewing the detailed overview of Inotiv's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOTV has been successfully added to your 